Company intelligence / Profile preview

Hengrui Therapeutics

Lianyungang, Jiangsu, Chinafoxchase.org ↗

Ownership: Private
Employees: ~24500
Development stage: Phase 3

Overview

Hengrui has achieved significant clinical milestones including positive global Phase 3 results with camrelizumab plus rivoceranib for advanced hepatocellular carcinoma. The company has over a dozen new molecular entities marketed in China and a robust pipeline spanning oncology and metabolic disease with more than ninety innovative drug candidates under development.

Therapeutic areas: Metabolic DisordersImmunologyOncologyNeurologyInfectious Diseases
Modalities: Small moleculesMonoclonal antibodies (mAbs)Protein engineering platforms (including mRNA technology)
Industry: Pharma

Drug pipeline

1 asset

SHR-1210

Clinical

Indications: Oncology

Beyond the preview

Go deeper on Hengrui Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hengrui Therapeutics.

Explore the full profile